Cure8 trial brief
This trial tests palmitoylethanolamide (PEA), a commercially available supplement with anti-inflammatory actions, as an add-on treatment for mild-to-moderate ulcerative colitis.
People with UC may be interested because it targets immune/inflammatory pathways and could offer a complementary option if proven effective and safe.
Patients with mild-to-moderate UC, clinicians treating IBD, and researchers interested in PPAR-α or supplement-based anti-inflammatory strategies.
This is a ClinicalTrials.gov record for a planned interventional trial testing palmitoylethanolamide (PEA) as a supplement for patients with active mild-to-moderate ulcerative colitis.
The study plans to randomize about 60 adults to PEA 600 mg/day versus placebo added to standard therapy and will measure disease activity, health-related quality of life, and inflammatory biomarkers.
The trial rationale described in the registry cites preclinical colitis models and small clinical studies in other inflammatory or pain conditions suggesting anti-inflammatory and analgesic effects of PEA, likely mediated in part via PPAR-α and related pathways.
The record notes prior safety data for PEA from non-IBD uses but does not present trial results—this is a NOT_YET_RECRUITING study listing a planned enrollment and interventions.
If you have UC and are curious about new complementary or adjunctive therapies, this trial is investigating PEA as an add-on to usual care; it does not change current standards of treatment and does not report outcomes yet.
Registry entry describes study design and rationale but contains no results; status is NOT_YET_RECRUITING. Evidence cited includes animal models and non-IBD clinical studies. Do not interpret this record as proof of benefit.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
The Phase 2b results suggest the investigational TL1A drug duvakitug improved clinical and endoscopic outcomes versus placebo in both ulcerative colitis and Crohn’s disease, which could expand future treatment options if...
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
